OncoMed receives vantictumab patent

|About: OncoMed Pharmaceuticals, Inc (OMED)|By:, SA News Editor

OncoMed Pharmaceuticals (OMED) says the U.S. Patent office has issued a patent related to the way vantictumab treats cancer.

Vantictumab is a Wnt pathway inhibitor and is currently in Phase 1 clinicals.

"The issuance of this patent further validates the novelty of this promising antibody and the innovative nature of OncoMed's ongoing discovery programs," CEO Paul Hastings says. (PR)